Anne-Marie Mes-Masson
Anne-Marie Mes-Masson
Professor, Departement of Medicine, Université de Montréal
Verified email at
Cited by
Cited by
ARID1A mutations in endometriosis-associated ovarian carcinomas
KC Wiegand, SP Shah, OM Al-Agha, Y Zhao, K Tse, T Zeng, J Senz, ...
New England Journal of Medicine 363 (16), 1532-1543, 2010
The molecular taxonomy of primary prostate cancer
A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ...
Cell 163 (4), 1011-1025, 2015
Cancer risks in BRCA2 mutation carriers
Breast Cancer Linkage Consortium
Journal of the National Cancer Institute 91 (15), 1310-1316, 1999
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene
Y Ben-Neriah, GQ Daley, AM Mes-Masson, ON Witte, D Baltimore
Science 233 (4760), 212-214, 1986
Oral contraceptives and the risk of hereditary ovarian cancer
SA Narod, H Risch, R Moslehi, A Dřrum, S Neuhausen, H Olsson, ...
New England Journal of Medicine 339 (7), 424-428, 1998
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
SA Narod, JS Brunet, P Ghadirian, M Robson, K Heimdal, SL Neuhausen, ...
The Lancet 356 (9245), 1876-1881, 2000
Mutation of FOXL2 in granulosa-cell tumors of the ovary
SP Shah, M Köbel, J Senz, RD Morin, BA Clarke, KC Wiegand, G Leung, ...
New England Journal of Medicine 360 (26), 2719-2729, 2009
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
Variation in cancer risks, by mutation position, in BRCA2 mutation carriers
D Thompson, D Easton, Breast Cancer Linkage Consortium
The American Journal of Human Genetics 68 (2), 410-419, 2001
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ...
Cell 173 (2), 291-304. e6, 2018
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics
J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ...
Cell 173 (2), 400-416. e11, 2018
Biobanking for better healthcare
PHJ Riegman, MM Morente, F Betsou, P De Blasio, P Geary, ...
Molecular oncology 2 (3), 213-222, 2008
Characterization of four novel epithelial ovarian cancer cell lines
DM Provencher, H Lounis, L Champoux, M Tetrault, EN Manderson, ...
In vitro cellular & developmental biology. Animal, 357-361, 2000
Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC)
M Zietarska, CM Maugard, A Filali‐Mouhim, M Alam‐Fahmy, PN Tonin, ...
Molecular Carcinogenesis: Published in cooperation with the University of …, 2007
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families
PN Tonin, AM Mes-Masson, PA Futreal, K Morgan, M Mahon, WD Foulkes, ...
The American Journal of Human Genetics 63 (5), 1341-1351, 1998
Machine learning identifies stemness features associated with oncogenic dedifferentiation
TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ...
Cell 173 (2), 338-354. e15, 2018
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
PO Gannon, AO Poisson, N Delvoye, R Lapointe, AM Mes-Masson, ...
Journal of immunological methods 348 (1-2), 9-17, 2009
The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma
CJ Ricketts, AA De Cubas, H Fan, CC Smith, M Lang, E Reznik, R Bowlby, ...
Cell reports 23 (1), 313-326. e5, 2018
The system can't perform the operation now. Try again later.
Articles 1–20